Rarity PBC Raises $4.6 Million Seed Financing to Advance Gene Therapy for ADA-SCID, led by Steve Oliveira from Nemean Asset Management.

Oct 29, 2025•about 2 months ago

Amount Raised

$4.6 Million

Round Type

seed

Los AngelesBiotechnologyHealth Care

Investors

Nemean Asset ManagementSteve Oliveira

Description

Rarity PBC has successfully closed a $4.6 million seed financing round aimed at accelerating the development of their gene therapy for ADA-SCID. The funding was led by biotech investor Steve Oliveira. Proceeds will support efforts towards establishing commercial-grade manufacturing and gaining FDA approval. Rarity aims to ensure all children with ADA-SCID can access the therapy.

Company Information

Company

Rarity PBC

Location

Los Angeles, California, United States

About

Rarity PBC is a Public Benefit Corporation focused on expanding access to transformative gene therapies for rare diseases. The company is dedicated to developing a one-time autologous hematopoietic stem cell gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID). Rarity aims to merge clinical validation with a public benefit mandate to enhance treatment access for patients. The team collaborates closely with researchers from UCLA to bring innovative therapies to market.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns